I-Mab Presents Promising Phase 1b Givastomig Combination Data for Gastric Cancers at ESMO GI 2025

I-Mab (NASDAQ:IMAB) is one of the best-performing NASDAQ stocks according to analysts. On July 2, I-Mab announced the presentation of positive Phase 1b combination data for givastomig at the European Society for Medical Oncology Gastrointestinal Cancers Congress 2025 (ESMO GI 2025) in Barcelona.

Givastomig, which is a bispecific antibody that targets Claudin 18.2 (CLDN18.2) and 4-1BB, was evaluated in combination with nivolumab (an anti-PD-1 checkpoint inhibitor) and mFOLFOX6 (a chemotherapy regimen including leucovorin calcium, fluorouracil, and oxaliplatin) as a first-line (1L) therapy for patients with CLDN18.2-positive gastric cancers.

The primary endpoint of the study was safety, and givastomig showed favorable overall tolerability. There were no Grade 3 or greater events for nausea and vomiting, and only one Grade 3 treatment-related adverse event/TRAE for increased liver enzymes.

I-Mab (NASDAQ:IMAB) is a biotech company that develops immuno-oncology agents for the treatment of cancer in the US.

While we acknowledge the potential of IMAB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.